SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (353)2/23/2003 1:54:02 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 469
 
>> Talk of a £111m cash bid from CLL <<

What does that translate to, per share, in real money?

:-)

Isn't that only about $3.10/share, when you throw in options?



To: nigel bates who wrote (353)2/23/2003 2:02:33 PM
From: scaram(o)uche  Respond to of 469
 
>> Would be really disappointing as the resulting entity would give about one fifth the 'leverage'. <<

The CAT merger is made in heaven, IMO. I want a cash offer, as I went overweight in that ADS bail at 2.35. But I'll vote no to anything below $4/share.

$2.35/share. What were they thinking?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News